Gufic Biosciences Ltd - 509079 - Corrigendum And Clarification To Intimation Dated May 29, 2026 Regarding Subscription To Shares Of Saraswat Co-Operative Bank Limited
Gufic BioSciences issued a corrigendum and clarification regarding its share subscription in Saraswat Co-operative Bank. The company stated this is a requirement for borrower members, not an acquisition or ownership investment, ensuring accurate reporting of its relationship.
Jun 02 2026 15:27:44
Gufic Biosciences Ltd - 509079 - Corrigendum And Clarification To Intimation Dated May 29, 2026 Regarding Subscription To Shares Of Saraswat Co-Operative Bank Limited
Gufic BioSciences issued a clarification regarding its subscription to shares of Saraswat Co-operative Bank. The company stated that this was a share-linkage requirement as an existing borrower with Rs.230 crore credit facilities, not a strategic investment or acquisition, ensuring no change in management or control.
Jun 02 2026 14:22:03
Gufic Biosciences Ltd - 509079 - Announcement under Regulation 30 (LODR)-Acquisition
Gufic BioSciences has approved a further investment of Rs. 5.75 crore by subscribing to 57.50 lakh equity shares in Saraswat Co-operative Bank. This strategic move aims to strengthen existing banking relationships and is part of the company's broader investment and treasury management strategy.
May 29 2026 22:53:30
Gufic Biosciences Ltd - 509079 - Corporate Action-Board approves Dividend
Gufic BioSciences board recommended a final dividend of Re. 0.10 per equity share for FY2025-26. This translates to 10% of the ₹1 face value, pending shareholder approval.
May 29 2026 22:44:27
Gufic Biosciences Ltd - 509079 - Board Meeting Intimation for Consideration And Approval Of, Inter Alia, Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended March 31, 2026 And To Recommend A Final Dividend, If Any, For The Financial Year 2025-26
Gufic BioSciences has scheduled a board meeting for May 29, 2026. The agenda includes approving the audited financial results for the quarter and financial year ended March 31, 2026, and considering a final dividend recommendation for FY26.
May 22 2026 17:28:45
Read More